Expected earnings - Castle Biosciences Inc.
Source: US Earnings Reports
Castle Biosciences Inc. (CSTL) is expected to report $-0.51 for Q2 2025
Castle Biosciences Inc.
NASDAQ: CSTL
CSTL Trading
1.08% G/L:
$25.32 Last:
82,523 Volume:
$25.40 Open:
CSTL Latest News
March 13, 2026 11:02:12 am
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 09, 2026 07:00:00 am
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 04, 2026 04:30:00 pm
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
March 03, 2026 04:30:00 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
CSTL Stock Data
$948,047,644
27,291,396
0.3%
60
N/A
Medical Diagnostics & Screening
Healthcare
US
Friendswood
